The Team Behind Redwood AI’s Technology Platforms

Mr. Dron is a highly experienced healthcare executive with a decade of multidisciplinary experience spanning clinical work, health technology, and leadership roles in both corporate and research settings. His expertise ranges from hands-on clinical diagnostics to leading high-level research teams and advancing real-world evidence applications in healthcare. Starting his career in clinical science, Louis honed his expertise in medical diagnostics, quality assurance, and hospital systems while working in top-tier hospitals in the UK. Over the years, Louis transitioned from clinical settings to high-impact director roles in research and development, where he led teams on projects that integrated real-world evidence, biostatistics, and epidemiology into healthcare decision-making. Louis also acts as an advisor to the Canadian Drug Agency and the Bill & Melinda Gates Foundation. He is a graduate of the University of Manchester and the University of Leicester.

Dr. Thorlund, with over 15 years of experience in data science and AI, is an established serial entrepreneur having been involved in the foundation of five Canadian-based businesses (with two successful multi-million dollar exits) over the past decade focused on health technologies. Kristian is an expert in AI and data analysis, with an extensive publication record and a citation profile that places him among the most highly cited researchers in his field. Alongside his business interests, Kristian is a part-time professor at McMaster University, acquiring over $6m in grants. He is a graduate of the University of Copenhagen and McMaster University.

Dr. Sammis is a worldwide leader in chemistry, acting as an accomplished academic with nearly two decades of experience. Currently, a professor at the University of British Columbia, he has built an exceptional teaching record, excelling across a wide range of courses, student evaluations, course development, creation of innovative materials, and teaching leadership. At his time at UBC, Dr. Sammis has acquired over $5.5m in grants. Outside of his research group being at the forefront of pioneering advances in radical and photochemical processes, Glenn has acted as an advisor for synthesis problems for over 10 private companies. He is a graduate of Stanford University and Harvard University.

Dr. Harari is a highly experienced statistician and data scientist with over 15 years of experience across various industries, including healthcare, pharmaceuticals, finance and academia. He has a proven track record in both practical data analysis and methodological research, consistently mentoring teams and advancing innovative solutions in healthcare, AI, and statistical science. In recent years, in addition to his tenure at Redwood AI, he served as a Head of Biostatistics at Purpose Life Science, and has previously worked for PayPal. He is a graduate of Ben Gurion University and Tel Aviv University.

Dr. Lat is a passionate researcher and data scientist with a decade of experience. His research spans multiple disciplines, including bioinformatics, biophysics, biochemistry, molecular biology, and DNA nanotechnology. He has also worked in biostatistics and data science, applying these tools to extract insights from complex datasets. He is a graduate of IIT Kanpur and Simon Fraser University.

Mr. Mah is a Chartered Professional Accountant and has nearly 8 years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023. He holds a Bachelor of Commerce degree, majoring in Accounting, from the University of Calgary and a CPA designation in Alberta, Canada.

Mr. Shahrokhi is an accomplished entrepreneur and business development executive with broad experience across the health, biotechnology, and mining industries. Over the course of his career, he has held numerous leadership roles and has been involved with a variety of successful private and public companies. Recognized for his strategic vision and ability to identify emerging opportunities, Mr. Shahrokhi has played an important role in helping businesses scale, strengthen their market position, and create long-term shareholder value.

With a focus on complex and high-growth opportunities, Mr. Shahrokhi has supported the development and expansion of a diverse range of businesses. His experience in corporate development, strategic growth, and value creation has supported companies through key stages of expansion and market development. Mr. Shahrokhi is the Founder and President of One51 Financial Services, a Vancouver-based firm providing accounting, corporate, and financial support services to public and private companies.

Mr. Mingay is a Research Data Scientist at the University of California, Berkeley’s Lawrence Berkeley National Laboratory, where he works at the intersection of biotechnology, computer science, and artificial intelligence, applying advanced methods to DNA sequencing technologies. He has over 10 years of experience in molecular biology and data science and holds a Master of Science in Microbiology and Immunology from the University of British Columbia and an Honours Bachelor of Science in Genetics and Medical Science from the University of Western Ontario. Mr. Mingay’s academic and research work has contributed to discoveries in biotechnology, cancer genomics, and epigenetics, resulting in publications in peer-reviewed journals including Nature Methods and Leukemia. He has also served as a scientific advisor and clinical diagnostics consultant, supporting research analysis and the implementation of cancer diagnostics across major hospital networks in the United States, and has been involved in academic teaching and mentorship initiatives, including founding a student-led data science organization at the University of British Columbia.

Mr. Darbandi is a sales strategist with over 30 years of experience leading national distribution and client relations across the professional wellness industry. He has driven growth for established brands including WELLA, AMERICAN CREW, and NIOXIN, securing major accounts and earning national sales awards. Mr. Darbandi brings experience in commercialization, customer engagement, and brand development, along with insight into scaling product adoption and managing complex stakeholder environments.

Dr. Dybul is a physician, scientist, and internationally recognized public health leader with more than two decades of experience in infectious disease research, global health policy, and large-scale healthcare program implementation. He served as United States Global AIDS Coordinator under President George W. Bush, where he led the implementation of the President’s Emergency Plan for AIDS Relief (PEPFAR), one of the largest international health initiatives in history.

Dr. Dybul held the rank of Rear Admiral in the U.S. Public Health Service and served as Assistant U.S. Surgeon General, reflecting his leadership in national and global public health initiatives. He later served as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, one of the world’s largest international health financing organizations dedicated to combating infectious diseases. Dr. Dybul is currently a Professor of Medicine at Georgetown University and has spent more than 25 years working as a clinician, researcher, and global health leader addressing infectious diseases, health systems development, and international health policy.

Over the course of his 25-year career, Dr. Roberts has held senior executive roles at leading companies including Nestlé, Abbott, Pharmavite, and Niagen Bioscience. His experience includes establishing a corporate venture fund at Nestlé focused on health innovation, co-leading at Abbott a public-private partnership with the University of Illinois that helped create the Center for Nutrition, Learning, and Memory, and expanding external research efforts at Niagen Bioscience, formerly ChromaDex, in support of peer-reviewed publications, regulatory progress, and new business areas focused on mitochondrial health. He also advises emerging companies and nonprofit organizations and has contributed to peer-reviewed work relating to scientific and technological innovation in human health. Dr. Roberts holds a Ph.D. in Toxicology from Cornell University, an MBA from Washington University in St. Louis, and a B.Sc. in Molecular Biology from Purdue University.

In his role as Public Health, Public Safety, and Defense Advisor, Dr. Roberts will provide strategic business and technical guidance to Redwood on the application of its artificial intelligence platform to complex challenges at the intersection of public health and public safety. His work focuses on translating advanced chemistry and AI capabilities into operational systems that support frontline professionals across law enforcement, healthcare, and regulatory decision-making. Dr. Roberts currently serves as Managing Director of Aidos Innovations, a nonprofit translational science institute developed in collaboration with the University of British Columbia and the IMAPP research program at Vancouver General Hospital. Aidos is focused on advancing technologies that bridge clinical insight, scientific innovation, and system-level implementation in response to the evolving opioid crisis and related public health challenges. Through this lens, Dr. Roberts brings experience in developing and operationalizing platforms such as Track & Trace, an integrated chemical intelligence system combining advanced analytical chemistry, data infrastructure, and cross-sector collaboration to generate actionable insights on illicit drug supply and its impact on communities.

Mr. O’Neill is the Chief Executive Officer of Quantum.IQ Technologies, bringing more than 35 years of experience in technology investing, advisory and leadership. Previously, He has co-founded numerous technology companies, including: Teleo Communications, acquired by Microsoft; Workfire Technologies, acquired by Packeteer; and Xtract AI Technologies, acquired by Patriot One; M37 Technology Partners; Railtown AI Technologies; and InMotion Energy Systems.

Dr. Holtham (PhD Computational Science) is the Chief Technology Officer of Quantum.IQ Technologies, bringing more than 20 years of experience in technology invention, development and leadership.  He has also co-founded numerous technology companies, including: Xtract AI Technologies, acquired by Patriot One; M37 Technology Partners; Railtown AI Technologies; and InMotion Energy Systems.

Mr. Dadwal is Founder and CEO of Ari & Co. Capital, a Vancouver-based private family-office. He is an entrepreneur and technology investor with experience across capital markets, early-stage technology companies and public safety, who served previously with the Royal Canadian Mounted Police as a Superintendent for more than 19 years, leading several high-profile law enforcement investigations. Mr. Dadwal has also received recognition including the International Association of Chiefs of Police 40 Under 40 Award, the Queen’s Jubilee Medal and a Governor General’s commendation.